ASC Therapeutics Doses First Patient with ASC618 Second-Generation Gene Therapy for Hemophilia A
Transformational in-vivo AAV gene therapy for hemophilia A Efficiently biosynthesized and secreted bioengineered factor VIII Potentially leads to lower therapeutic dose, reduced cost, and extended